Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 BridgeBio PharmaMirati TherapeuticsBausch Health CompaniesGrifolsDr. Reddy's Laboratories
SymbolNASDAQ:BBIONASDAQ:MRTXNYSE:BHCNASDAQ:GRFSNYSE:RDY
Price Information
Current Price$55.12$158.19$30.03$17.98$65.01
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score2.01.61.71.31.3
Analysis Score4.53.32.30.01.5
Community Score2.52.92.42.12.1
Dividend Score0.00.00.01.71.7
Ownership Score2.51.70.80.00.0
Earnings & Valuation Score0.60.03.12.51.3
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$72.89$218.57$32.58N/A$70.00
% Upside from Price Target32.24% upside38.17% upside8.50% upsideN/A7.68% upside
Trade Information
Market Cap$8.21 billion$8.01 billion$10.68 billion$12.36 billion$10.81 billion
Beta0.821.641.470.590.41
Average Volume1,026,278429,6914,805,146944,932208,712
Sales & Book Value
Annual Revenue$40.56 million$3.34 million$8.60 billion$5.71 billion$2.32 billion
Price / Sales202.432,398.141.242.164.67
CashflowN/AN/A$11.96 per share$1.55 per share$3.44 per share
Price / CashN/AN/A2.5111.5818.92
Book Value$3.83 per share$9.67 per share$3.22 per share$11.15 per share$12.41 per share
Price / Book14.3916.369.331.615.24
Profitability
Net Income$-260,590,000.00$-213,260,000.00$-1,788,000,000.00$700.16 million$259 million
EPS($2.48)($5.69)$4.43$1.17$2.79
Trailing P/E RatioN/AN/AN/A16.0553.73
Forward P/E RatioN/AN/A6.9011.9126.75
P/E GrowthN/AN/A0.541.30N/A
Net MarginsN/AN/A-23.92%12.79%8.23%
Return on Equity (ROE)-109.88%-60.01%173.20%10.65%16.33%
Return on Assets (ROA)-48.54%-54.21%4.21%4.79%10.79%
Dividend
Annual PayoutN/AN/AN/A$0.14$0.27
Dividend YieldN/AN/AN/A0.78%0.42%
Three-Year Dividend GrowthN/AN/AN/A-49.65%6.19%
Payout RatioN/AN/AN/A11.97%9.68%
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio2.19%N/A37.16%0.95%0.04%
Current Ratio9.85%8.84%1.20%2.93%1.72%
Quick Ratio9.85%8.84%0.94%1.33%1.20%
Ownership Information
Institutional Ownership Percentage95.53%94.92%62.92%15.15%12.89%
Insider Ownership Percentage40.32%4.10%12.14%N/A2.00%
Miscellaneous
Employees38519921,60023,65521,650
Shares Outstanding148.96 million50.63 million355.62 million687.55 million166.29 million
Next Earnings Date5/12/2021 (Estimated)5/6/2021 (Estimated)5/4/2021 (Confirmed)4/20/2021 (Estimated)5/19/2021 (Estimated)
OptionableNot OptionableOptionableOptionableOptionableOptionable
SourceHeadline
Dr. Reddys gets emergency use authorization for Sputnik V in IndiaDr. Reddy's gets emergency use authorization for Sputnik V in India
seekingalpha.com - April 14 at 8:21 PM
Dr. Reddys Laboratories (NYSE:RDY) Shares Gap Down to $65.85Dr. Reddy's Laboratories (NYSE:RDY) Shares Gap Down to $65.85
americanbankingnews.com - April 13 at 11:50 AM
Dr. Reddy’s Receives Approval For Emergency Use Of Sputnik V In IndiaDr. Reddy’s Receives Approval For Emergency Use Of Sputnik V In India
finance.yahoo.com - April 13 at 7:45 AM
Dr. Reddys Stock Is Trading Higher As Sputnik V Vaccine Gets Emergency Use Nod In India: ReportDr. Reddy's Stock Is Trading Higher As Sputnik V Vaccine Gets Emergency Use Nod In India: Report
finance.yahoo.com - April 12 at 2:51 PM
Dr. Reddys Laboratories (NYSE:RDY) Shares Gap Up to $63.92Dr. Reddy's Laboratories (NYSE:RDY) Shares Gap Up to $63.92
americanbankingnews.com - April 12 at 11:12 AM
RDY Crosses Above Key Moving Average LevelRDY Crosses Above Key Moving Average Level
nasdaq.com - April 10 at 7:28 PM
Dr. Reddys Laboratories (NYSE:RDY) Upgraded at Zacks Investment ResearchDr. Reddy's Laboratories (NYSE:RDY) Upgraded at Zacks Investment Research
marketbeat.com - April 9 at 10:47 AM
Dr. Reddys Laboratories Announces the Launch of a Generic Version of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg in the U.S. MaDr. Reddy's Laboratories Announces the Launch of a Generic Version of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg in the U.S. Ma
us.acrofan.com - April 7 at 7:23 AM
Dr. Reddys Laboratories launches generic version of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg in the U.S. MarketDr. Reddy's Laboratories launches generic version of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg in the U.S. Market
equitybulls.com - April 7 at 7:23 AM
Dr. Reddys Laboratories Announces the Launch of a Generic Version of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg in the U.S. MarketDr. Reddy's Laboratories Announces the Launch of a Generic Version of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg in the U.S. Market
finance.yahoo.com - April 7 at 7:23 AM
Dr. Reddys Laboratories Ltd. ADRDr. Reddy's Laboratories Ltd. ADR
wsj.com - March 31 at 3:13 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy’s Laboratories Limited - RDYSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy’s Laboratories Limited - RDY
finance.yahoo.com - March 10 at 12:48 AM
Dr. Reddys requested by India to give more data for Sputnik V approvalDr. Reddy's requested by India to give more data for Sputnik V approval
seekingalpha.com - February 27 at 12:10 PM
Dr. Reddys Starts EUA Process For Russias Sputnik V COVID-19 Vaccine In IndiaDr. Reddy's Starts EUA Process For Russia's Sputnik V COVID-19 Vaccine In India
finance.yahoo.com - February 19 at 12:43 PM
Dr. Reddy’s Initiates Process for Emergency Use Authorization of Sputnik VDr. Reddy’s Initiates Process for Emergency Use Authorization of Sputnik V
apnews.com - February 19 at 7:43 AM
Dr. Reddys Begins EUA Process In India For Sputnik V Vaccine - Quick FactsDr. Reddy's Begins EUA Process In India For Sputnik V Vaccine - Quick Facts
nasdaq.com - February 19 at 7:43 AM
Dr. Reddys Initiates Process for Emergency Use Authorization of Sputnik VDr. Reddy's Initiates Process for Emergency Use Authorization of Sputnik V
finance.yahoo.com - February 19 at 7:43 AM
Dr. Reddys Launches Generic Version Of Xeloda Tablets - Quick FactsDr. Reddy's Launches Generic Version Of Xeloda Tablets - Quick Facts
nasdaq.com - February 17 at 8:17 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy’s Laboratories Limited - RDYSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy’s Laboratories Limited - RDY
finance.yahoo.com - February 13 at 6:33 PM
Dr. Reddys Laboratories Announces the Launch of Vigabatrin Tablets, USP in the U.S. Market | MorningstarDr. Reddy's Laboratories Announces the Launch of Vigabatrin Tablets, USP in the U.S. Market | Morningstar
morningstar.com - February 2 at 5:33 AM
Dr. Reddys Launches Generic Version Of Sabril Tablets - Quick FactsDr. Reddy's Launches Generic Version Of Sabril Tablets - Quick Facts
nasdaq.com - February 2 at 5:33 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddys Laboratories Limited - RDYSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
finance.yahoo.com - February 2 at 5:33 AM
Dr. Reddys Laboratories Announces the Launch of Vigabatrin Tablets, USP in the U.S. MarketDr. Reddy's Laboratories Announces the Launch of Vigabatrin Tablets, USP in the U.S. Market
finance.yahoo.com - February 2 at 5:33 AM
Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Dr. Reddys Laboratories Limited (RDY) InvestigationBronstein, Gewirtz & Grossman, LLC Notifies Investors of Dr. Reddy's Laboratories Limited (RDY) Investigation
finance.yahoo.com - February 1 at 12:32 PM
Dr. Reddy’s and GRA Announce Clinically Meaningful Data from Avigan Pivotal StudiesDr. Reddy’s and GRA Announce Clinically Meaningful Data from Avigan Pivotal Studies
apnews.com - January 30 at 12:41 AM
Dr. Reddys Laboratories Limited: Dr. Reddy Reports a Strong Third Quarter, Yet Short of Unreasonable Consensus ExpectationsDr. Reddy's Laboratories Limited: Dr. Reddy Reports a Strong Third Quarter, Yet Short of Unreasonable Consensus Expectations
finance.yahoo.com - January 30 at 12:41 AM
DateCompanyBrokerageAction
4/11/2021BridgeBio PharmaSVB LeerinkReiterated Rating
3/23/2021BridgeBio PharmaJefferies Financial GroupReiterated Rating
3/22/2021BridgeBio PharmaThe Goldman Sachs GroupBoost Price Target
3/20/2021BridgeBio PharmaMizuhoInitiated Coverage
2/22/2021BridgeBio PharmaJPMorgan Chase & Co.Initiated Coverage
1/11/2021BridgeBio PharmaHC WainwrightBoost Price Target
12/14/2020BridgeBio PharmaBTIG ResearchBoost Price Target
11/5/2020BridgeBio PharmaPiper SandlerBoost Price Target
10/6/2020BridgeBio PharmaBMO Capital MarketsBoost Price Target
6/25/2020BridgeBio PharmaBank of AmericaInitiated Coverage
3/8/2021Mirati TherapeuticsOppenheimerLower Price Target
12/16/2020Mirati TherapeuticsCredit Suisse GroupBoost Price Target
12/8/2020Mirati TherapeuticsEvercore ISIInitiated Coverage
12/8/2020Mirati TherapeuticsJMP SecuritiesInitiated Coverage
11/10/2020Mirati TherapeuticsGuggenheimDowngrade
10/29/2020Mirati TherapeuticsBarclaysBoost Price Target
10/8/2020Mirati TherapeuticsCSFBBoost Price Target
3/4/2021Bausch Health CompaniesMorgan StanleyBoost Price Target
3/2/2021Bausch Health CompaniesCitigroupBoost Price Target
2/17/2021Bausch Health CompaniesRoyal Bank of CanadaUpgrade
10/28/2020Bausch Health CompaniesWells Fargo & CompanyLower Price Target
3/17/2021GrifolsHSBCUpgrade
2/12/2021GrifolsBerenberg BankReiterated Rating
3/27/2020GrifolsKepler Capital MarketsReiterated Rating
2/3/2021Dr. Reddy's LaboratoriesInvestecUpgrade
4/21/2020Dr. Reddy's LaboratoriesNomura InstinetReiterated Rating
7/1/2019Dr. Reddy's LaboratoriesMacquarieUpgrade
6/20/2019Dr. Reddy's LaboratoriesDeutsche Bank AktiengesellschaftInitiated Coverage
2/4/2019Dr. Reddy's LaboratoriesCL KingUpgrade
(Data available from 4/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.